Literature DB >> 15354014

Management of jugular paragangliomas: the Gruppo Otologico experience.

Mario Sanna1, Yogesh Jain, Giuseppe De Donato, Lorenzo Lauda, Abdelkader Taibah.   

Abstract

OBJECTIVE: The objective of this study was to review the outcome of surgical management in patients of jugular paragangliomas. STUDY
DESIGN: We conducted a retrospective case review.
SETTING: Tertiary care otology and skull base center.
MATERIALS AND METHODS: Fifty-five patients with the diagnosis of a jugular paraganglioma (Fisch Class C and D Glomus Jugulare) were managed over a period of 15 years. All patients with adequate follow up and complete records (53 cases) were reviewed with emphasis on the results of surgical management and the factors influencing them. INTERVENTION: All 53 patients were managed with a view to surgically extirpate the tumor. The primary approach was the infratemporal fossa approach-Type A used in the majority of the patients. In eight cases, the procedure was staged owing to the presence of large intracranial extension. Three patients required additional procedures to ameliorate the after-effects of lower cranial nerve resection.
RESULTS: Gross total tumor removal was achieved in 49 patients. There were five cases of recurrence. Coupled with the residual tumors in five patients, the surgical control achieved was 83%. There was no perioperative mortality. There were two cases of postoperative cerebrospinal fluid leak, both of which required surgical exploration and closure. The facial nerve was resected in seven patients. The overall preservation rate of clinically uninvolved lower cranial nerves was 75%.
CONCLUSIONS: The low level of complications along with a high surgical control achieved makes surgery the primary mode of treatment in the vast majority of these tumors, regardless of the size and location.

Entities:  

Mesh:

Year:  2004        PMID: 15354014     DOI: 10.1097/00129492-200409000-00025

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  22 in total

1.  Temporal Bone Paraganglioma: Hearing Outcomes and Rehabilitation.

Authors:  David D Walker; Seilesh Babu
Journal:  J Neurol Surg B Skull Base       Date:  2019-02-14

2.  Rehabilitation after treatment for jugular foramen lesions.

Authors:  A D Cheesman; Annette M Kelly
Journal:  Skull Base       Date:  2009-01

3.  Consensus statement and guidelines on the management of paragangliomas of the head and neck.

Authors:  Mislav Gjuric; Michael Gleeson
Journal:  Skull Base       Date:  2009-01

4.  Combined endovascular-surgical management of the internal carotid artery in complex tympanojugular paragangliomas.

Authors:  Mario Sanna; Paolo Piazza; Giuseppe De Donato; Roberto Menozzi; Maurizio Falcioni
Journal:  Skull Base       Date:  2009-01

5.  Nonvascular lesions of the jugular foramen: the gruppo otologico experience.

Authors:  Mario Sanna; Giuseppe De Donato; Filippo Di Lella; Maurizio Falcioni; Nitin Aggrawal; Guglielmo Romano
Journal:  Skull Base       Date:  2009-01

6.  Treatment of recurrent and residual glomus jugulare tumors.

Authors:  Jose N Fayad; Marc S Schwartz; Derald E Brackmann
Journal:  Skull Base       Date:  2009-01

7.  Transmastoid-infralabyrinthine tailored surgery of jugular paragangliomas.

Authors:  Mislav Gjuric; Mario Bilic
Journal:  Skull Base       Date:  2009-01

8.  Primary parapharyngeal tumours: a review of 21 cases.

Authors:  Claudio Caldarelli; S Bucolo; R Spisni; D Destito
Journal:  Oral Maxillofac Surg       Date:  2014-04-24

Review 9.  Surgery of the ear and the lateral skull base: pitfalls and complications.

Authors:  Bernhard Schick; Julia Dlugaiczyk
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2013-12-13

10.  Lower cranial nerves function after surgical treatment of Fisch Class C and D tympanojugular paragangliomas.

Authors:  Andrea Bacciu; Marimar Medina; Hassen Ait Mimoune; Flavia D'Orazio; Enrico Pasanisi; Giorgio Peretti; Mario Sanna
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-12-12       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.